USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: AM BIOTECHNOLOGIES, LLC
City: HOUSTON
State: TX
Zip+4: 77034-4509
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: (409) 771-1981

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,409,475.00 7
SBIR Phase II $2,545,804.00 3

Award List:

New Reagents for Synthesizing Nuclease-resistant siRNA

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $199,202.00
Abstract:
DESCRIPTION (provided by applicant): The siRNA molecule needs better protection from nuclease degradation before it can be effectively used as a therapeutic. AM Biotechnologies (AM) will address this critical issue by developing ribonucleoside thiophospho ramidite (ABz, CBz, GIbu and U) reagents… More

Thioaptamer Diagnostic System

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: NASA
Principal Investigator: Xianbin Yang, Principal Investigator
Award Amount: $100,000.00
Abstract:
AM Biotechnologies (AM) will develop a diagnostic system in response to SBIR Topic X10.01 Reusable Diagnostic Lab Technology that will simultaneously detect and quantify numerous protein biomarkers with excellent sensitivity. AM will enhance the current clinical gold standard immunoassay… More

Optimize RNA-aptamer for Biomarker Molecule CD30

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Xianbin Yang
Award Amount: $123,605.00
Abstract:
DESCRIPTION (provided by applicant): Systemic Anaplastic Large Cell Lymphoma (ALCL) is the most common T-cell lymphoma in children. ALCL is characterized by its anaplastic cell morphology and high level expression of CD30 on the cell surface. This diffuse and homogeneous CD30 expression in ALCL… More

Thioaptamer Diagnostic System

Award Year / Program / Phase: 2010 / SBIR / Phase II
Agency: NASA
Principal Investigator: Xianbin Yang, Principal Investigator
Award Amount: $600,000.00
Abstract:
AM Biotechnologies (AM) in partnership with Sandia National Laboratories will develop a Thioaptamer Diagnostic System (TDS) in response to Topic X10.01 Reusable Diagnostic Lab Technology. The TDS will quickly quantify clinically relevant biomarkers in flight using only microliters of virtually any… More

New Reagents for Synthesis of High Potency siRNA

Award Year / Program / Phase: 2010 / SBIR / Phase II
Agency: HHS
Principal Investigator: Xianbin Yang
Award Amount: $949,235.00
Abstract:
DESCRIPTION (provided by applicant): New Reagents for Synthesis of High Potency siRNAs Abstract Since the discovery of short interfering RNA (siRNA) molecules in the late 1990s, siRNA technology has developed rapidly as a powerful tool for functional genom ic analysis, target validation and… More

THIOAPTAMER CAPTURE FOR ADDICTION-RELEVANT PROTEINS

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Ross Durland
Award Amount: $200,000.00
Abstract:
AM Biotechnologies (AM) will develop renewable thioaptamer protein capture reagents to ten proteins related to drug addiction. Thioaptamers are a type of aptamer containing phosphorodithioate linkages and other modifications that have excellent affinity and specificity for proteins. Because of the… More

New Reagents for the Synthesis of Phosphorodithioate-Modified 2'-O-Methyl RNAs

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Xianbin Yang – 832-379-2175
Award Amount: $156,729.00
Abstract:
DESCRIPTION (provided by applicant): Functional RNA molecules such as aptamers, siRNAs, miRNAs, and related compounds have enormous potential as human therapeutics and as tools for elucidating gene regulation in vivo. To reach this potential, such molecules must be highly potent and highly nuclease… More

New Building Blocks for the Synthesis of Modified RNAs

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Xianbin Yang – 832-379-2175
Award Amount: $180,115.00
Abstract:
DESCRIPTION (provided by applicant): Functional RNA molecules such as aptamers, siRNAs, miRNAs, and related compounds have enormous potential as human therapeutics and as tools for elucidating gene regulation in vivo. To reach this potential, such molecules must be highly potent and highly nuclease… More

Probes targeting multiple myeloma in the context of tumor-stromal interactions

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Curtis H. Lam – 832-379-2170
Award Amount: $449,824.00
Abstract:
DESCRIPTION: AM Biotechnologies (AM) is developing an easy-to-use kit that enables a technician in a life science laboratory to rapidly develop renewable X-Aptamer (XA) affinity reagents at a reasonable price. Affinity reagents are widely used in research, diagnostic, and clinical applications.… More

New Reagents for RNA-based Therapeutic Technologies

Award Year / Program / Phase: 2013 / SBIR / Phase II
Agency: HHS
Principal Investigator: Xianbin Yang – 832-379-2175
Award Amount: $996,569.00
Abstract:
DESCRIPTION: New Reagents for RNA-based Therapeutic Technologies Abstract Functional RNA molecules such as aptamers, siRNAs, miRNAs, and related compounds have enormous potential as human therapeutics and as tools for elucidating gene regulation in vivo.To reach this potential, such molecules must… More